{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T17:55:49Z","timestamp":1770918949941,"version":"3.50.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T00:00:00Z","timestamp":1728864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T00:00:00Z","timestamp":1728864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["5R01 NS045630"],"award-info":[{"award-number":["5R01 NS045630"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["F30NS125928"],"award-info":[{"award-number":["F30NS125928"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002721","name":"Charcot-Marie-Tooth Association","doi-asserted-by":"publisher","award":["Charcot-Marie-Tooth Association"],"award-info":[{"award-number":["Charcot-Marie-Tooth Association"]}],"id":[{"id":"10.13039\/100002721","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell. Mol. Life Sci."],"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Increasing cyclic GMP activates 26S proteasomes via phosphorylation by Protein Kinase G and stimulates the intracellular degradation of misfolded proteins. Therefore, agents that raise cGMP may be useful therapeutics against neurodegenerative diseases and other diseases in which protein degradation is reduced and misfolded proteins accumulate, including Charcot Marie Tooth 1A and 1B peripheral neuropathies, for which there are no treatments. Here we increased cGMP in the S63del mouse model of CMT1B by treating for three weeks with either the phosphodiesterase 5 inhibitor tadalafil, or the brain-penetrant soluble guanylyl cyclase stimulator CYR119. Both molecules activated proteasomes in the affected peripheral nerves, reduced polyubiquitinated proteins, and improved myelin thickness and nerve conduction. CYR119 increased cGMP more than tadalafil in the peripheral nerves of S63del mice and elicited greater biochemical and functional improvements. To determine whether raising cGMP could be beneficial in other neuropathies, we first showed that polyubiquitinated proteins and the disease-causing protein accumulate in the sciatic nerves of the C3 mouse model of CMT1A. Treatment of these mice with CYR119 reduced the levels of polyubiquitinated proteins and the disease-causing protein, presumably by increasing their degradation, and improved myelination, nerve conduction, and motor coordination. Thus, pharmacological agents that increase cGMP are promising treatments for CMT1 neuropathies and may be useful against other proteotoxic and neurodegenerative diseases.<\/jats:p>","DOI":"10.1007\/s00018-024-05463-1","type":"journal-article","created":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T05:01:47Z","timestamp":1728882107000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Pharmacologically increasing cGMP improves proteostasis and reduces neuropathy in mouse models of CMT1"],"prefix":"10.1007","volume":"81","author":[{"given":"Seth M.","family":"Moore","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Gawron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mckayla","family":"Stevens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leandro N.","family":"Marziali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmanuel S.","family":"Buys","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G. Todd","family":"Milne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Laura","family":"Feltri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4411-2659","authenticated-orcid":false,"given":"Jordan J.S.","family":"VerPlank","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,10,14]]},"reference":[{"key":"5463_CR1","doi-asserted-by":"publisher","first-page":"2236","DOI":"10.1007\/s13311-021-01145-z","volume":"18","author":"V Fridman","year":"2021","unstructured":"Fridman V, Saporta MA (2021) Mechanisms and treatments in demyelinating CMT. Neurother J Am Soc Exp Neurother 18:2236\u20132268. https:\/\/doi.org\/10.1007\/s13311-021-01145-z","journal-title":"Neurother J Am Soc Exp Neurother"},{"key":"5463_CR2","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1111\/jns.12539","volume":"28","author":"A Bolino","year":"2023","unstructured":"Bolino A, D\u2019Antonio M (2023) Recent advances in the treatment of Charcot-Marie-tooth neuropathies. J Peripher Nerv Syst 28:134\u2013149. https:\/\/doi.org\/10.1111\/jns.12539","journal-title":"J Peripher Nerv Syst"},{"key":"5463_CR3","doi-asserted-by":"publisher","unstructured":"Siems SB, Jahn O, Eichel MA et al (2020) Proteome profile of peripheral myelin in healthy mice and in a neuropathy model. Elife 9. https:\/\/doi.org\/10.7554\/eLife.51406","DOI":"10.7554\/eLife.51406"},{"key":"5463_CR4","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1002\/acn3.543","volume":"5","author":"Y Bai","year":"2018","unstructured":"Bai Y, Wu X, Brennan KM et al (2018) Myelin protein zero mutations and the unfolded protein response in Charcot Marie Tooth disease type 1B. Ann Clin Transl Neurol 5:445\u2013455. https:\/\/doi.org\/10.1002\/acn3.543","journal-title":"Ann Clin Transl Neurol"},{"key":"5463_CR5","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.neuron.2007.12.021","volume":"57","author":"M Pennuto","year":"2008","unstructured":"Pennuto M, Tinelli E, Malaguti M et al (2008) Ablation of the UPR-mediator CHOP restores motor function and reduces demyelination in Charcot-Marie-tooth 1B mice. Neuron 57:393\u2013405. https:\/\/doi.org\/10.1016\/j.neuron.2007.12.021","journal-title":"Neuron"},{"key":"5463_CR6","doi-asserted-by":"publisher","first-page":"11350","DOI":"10.1523\/JNEUROSCI.1637-16.2016","volume":"36","author":"M Sidoli","year":"2016","unstructured":"Sidoli M, Musner N, Silvestri N et al (2016) Ablation of Perk in Schwann Cells Improves Myelination in the S63del Charcot-Marie-tooth 1B Mouse. J Neurosci 36:11350\u201311361. https:\/\/doi.org\/10.1523\/JNEUROSCI.1637-16.2016","journal-title":"J Neurosci"},{"key":"5463_CR7","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1002\/glia.23251","volume":"66","author":"JJS VerPlank","year":"2018","unstructured":"VerPlank JJS, Lokireddy S, Feltri ML et al (2018) Impairment of protein degradation and proteasome function in hereditary neuropathies. Glia 66:379\u2013395. https:\/\/doi.org\/10.1002\/glia.23251","journal-title":"Glia"},{"key":"5463_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-3-030-58971-4_1","volume":"96","author":"Y Mao","year":"2021","unstructured":"Mao Y (2021) Structure, Dynamics and function of the 26S proteasome. Subcell Biochem 96:1\u2013151. https:\/\/doi.org\/10.1007\/978-3-030-58971-4_1","journal-title":"Subcell Biochem"},{"key":"5463_CR9","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1038\/s41418-020-00667-x","volume":"28","author":"F Le Guerrou\u00e9","year":"2021","unstructured":"Le Guerrou\u00e9 F, Youle RJ (2021) Ubiquitin signaling in neurodegenerative diseases: an autophagy and proteasome perspective. Cell Death Differ 28:439\u2013454. https:\/\/doi.org\/10.1038\/s41418-020-00667-x","journal-title":"Cell Death Differ"},{"key":"5463_CR10","doi-asserted-by":"publisher","first-page":"117906951879467","DOI":"10.1177\/1179069518794675","volume":"12","author":"DM Smith","year":"2018","unstructured":"Smith DM (2018) Could a common mechanism of protein degradation impairment Underlie many neurodegenerative diseases? J Exp Neurosci 12:1179069518794675. https:\/\/doi.org\/10.1177\/1179069518794675","journal-title":"J Exp Neurosci"},{"key":"5463_CR11","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/j.cell.2017.04.023","volume":"169","author":"GA Collins","year":"2017","unstructured":"Collins GA, Goldberg AL (2017) The logic of the 26S proteasome. Cell 169:792\u2013806. https:\/\/doi.org\/10.1016\/j.cell.2017.04.023","journal-title":"Cell"},{"key":"5463_CR12","doi-asserted-by":"publisher","first-page":"3355","DOI":"10.1042\/BCJ20160809","volume":"474","author":"JJS VerPlank","year":"2017","unstructured":"VerPlank JJS, Goldberg AL (2017) Regulating protein breakdown through proteasome phosphorylation. Biochem J 474:3355\u20133371. https:\/\/doi.org\/10.1042\/BCJ20160809","journal-title":"Biochem J"},{"key":"5463_CR13","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/ncb3289","volume":"18","author":"X Guo","year":"2016","unstructured":"Guo X, Wang X, Wang Z et al (2016) Site-specific proteasome phosphorylation controls cell proliferation and tumorigenesis. Nat Cell Biol 18:202\u2013212. https:\/\/doi.org\/10.1038\/ncb3289","journal-title":"Nat Cell Biol"},{"key":"5463_CR14","doi-asserted-by":"publisher","first-page":"E7176","DOI":"10.1073\/pnas.1522332112","volume":"112","author":"S Lokireddy","year":"2015","unstructured":"Lokireddy S, Kukushkin NV, Goldberg AL (2015) cAMP-induced phosphorylation of 26S proteasomes on Rpn6\/PSMD11 enhances their activity and the degradation of misfolded proteins. Proc Natl Acad Sci U S A 112:E7176\u2013E7185. https:\/\/doi.org\/10.1073\/pnas.1522332112","journal-title":"Proc Natl Acad Sci U S A"},{"key":"5463_CR15","doi-asserted-by":"publisher","first-page":"4228","DOI":"10.1073\/pnas.1809254116","volume":"116","author":"JJS VerPlank","year":"2019","unstructured":"VerPlank JJS, Lokireddy S, Zhao J, Goldberg AL (2019) 26S proteasomes are rapidly activated by diverse hormones and physiological states that raise cAMP and cause Rpn6 phosphorylation. Proc Natl Acad Sci U S A 116:4228\u20134237. https:\/\/doi.org\/10.1073\/pnas.1809254116","journal-title":"Proc Natl Acad Sci U S A"},{"key":"5463_CR16","doi-asserted-by":"publisher","first-page":"14220","DOI":"10.1073\/pnas.2003277117","volume":"117","author":"JJS VerPlank","year":"2020","unstructured":"VerPlank JJS, Tyrkalska SD, Fleming A et al (2020) cGMP via PKG activates 26S proteasomes and enhances degradation of proteins, including ones that cause neurodegenerative diseases. Proc Natl Acad Sci U S A 117:14220\u201314230. https:\/\/doi.org\/10.1073\/pnas.2003277117","journal-title":"Proc Natl Acad Sci U S A"},{"key":"5463_CR17","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1038\/nm.4011","volume":"22","author":"N Myeku","year":"2016","unstructured":"Myeku N, Clelland CL, Emrani S et al (2016) Tau-driven 26S proteasome impairment and cognitive dysfunction can be prevented early in disease by activating cAMP-PKA signaling. Nat Med 22:46\u201353. https:\/\/doi.org\/10.1038\/nm.4011","journal-title":"Nat Med"},{"key":"5463_CR18","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1161\/CIRCULATIONAHA.113.001971","volume":"128","author":"MJ Ranek","year":"2013","unstructured":"Ranek MJ, Terpstra EJM, Li J et al (2013) Protein kinase g positively regulates proteasome-mediated degradation of misfolded proteins. Circulation 128:365\u2013376. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.113.001971","journal-title":"Circulation"},{"key":"5463_CR19","doi-asserted-by":"publisher","first-page":"eaaw5870","DOI":"10.1126\/sciadv.aaw5870","volume":"5","author":"H Zhang","year":"2019","unstructured":"Zhang H, Pan B, Wu P et al (2019) PDE1 inhibition facilitates proteasomal degradation of misfolded proteins and protects against cardiac proteinopathy. Sci Adv 5:eaaw5870. https:\/\/doi.org\/10.1126\/sciadv.aaw5870","journal-title":"Sci Adv"},{"key":"5463_CR20","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1093\/brain\/awab249","volume":"145","author":"JJS VerPlank","year":"2022","unstructured":"VerPlank JJS, Gawron J, Silvestri NJ et al (2022) Raising cGMP restores proteasome function and myelination in mice with a proteotoxic neuropathy. Brain 145:168\u2013178. https:\/\/doi.org\/10.1093\/brain\/awab249","journal-title":"Brain"},{"key":"5463_CR21","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1124\/pr.110.002907","volume":"62","author":"SH Francis","year":"2010","unstructured":"Francis SH, Busch JL, Corbin JD, Sibley D (2010) cGMP-dependent protein kinases and cGMP phosphodiesterases in nitric oxide and cGMP action. Pharmacol Rev 62:525\u2013563. https:\/\/doi.org\/10.1124\/pr.110.002907","journal-title":"Pharmacol Rev"},{"key":"5463_CR22","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1038\/s41573-019-0033-4","volume":"18","author":"GS Baillie","year":"2019","unstructured":"Baillie GS, Tejeda GS, Kelly MP (2019) Therapeutic targeting of 3\u2019,5\u2019-cyclic nucleotide phosphodiesterases: inhibition and beyond. Nat Rev Drug Discov 18:770\u2013796. https:\/\/doi.org\/10.1038\/s41573-019-0033-4","journal-title":"Nat Rev Drug Discov"},{"key":"5463_CR23","doi-asserted-by":"publisher","unstructured":"Sandner P, Zimmer DP, Milne GT et al (2019) Soluble Guanylate Cyclase stimulators and activators. https:\/\/doi.org\/10.1007\/164_2018_197. Handb Exp Pharmacol","DOI":"10.1007\/164_2018_197"},{"key":"5463_CR24","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1186\/s12974-021-02275-z","volume":"18","author":"SS Correia","year":"2021","unstructured":"Correia SS, Liu G, Jacobson S et al (2021) The CNS-penetrant soluble guanylate cyclase stimulator CYR119 attenuates markers of inflammation in the central nervous system. J Neuroinflammation 18:213. https:\/\/doi.org\/10.1186\/s12974-021-02275-z","journal-title":"J Neuroinflammation"},{"key":"5463_CR25","doi-asserted-by":"publisher","first-page":"2358","DOI":"10.1523\/JNEUROSCI.3819-05.2006","volume":"26","author":"L Wrabetz","year":"2006","unstructured":"Wrabetz L, D\u2019Antonio M, Pennuto M et al (2006) Different intracellular pathomechanisms produce diverse myelin protein zero neuropathies in transgenic mice. J Neurosci 26:2358\u20132368. https:\/\/doi.org\/10.1523\/JNEUROSCI.3819-05.2006","journal-title":"J Neurosci"},{"key":"5463_CR26","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1038\/ng1195-274","volume":"11","author":"K Adlkofer","year":"1995","unstructured":"Adlkofer K, Martini R, Aguzzi A et al (1995) Hypermyelination and demyelinating peripheral neuropathy in Pmp22-deficient mice. Nat Genet 11:274\u2013280. https:\/\/doi.org\/10.1038\/ng1195-274","journal-title":"Nat Genet"},{"key":"5463_CR27","doi-asserted-by":"publisher","first-page":"30","DOI":"10.3389\/fmolb.2019.00030","volume":"6","author":"R Motosugi","year":"2019","unstructured":"Motosugi R, Murata S (2019) Dynamic regulation of Proteasome expression. Front Mol Biosci 6:30. https:\/\/doi.org\/10.3389\/fmolb.2019.00030","journal-title":"Front Mol Biosci"},{"key":"5463_CR28","doi-asserted-by":"publisher","first-page":"3180","DOI":"10.1093\/brain\/awv241","volume":"138","author":"O Sanmaneechai","year":"2015","unstructured":"Sanmaneechai O, Feely S, Scherer SS et al (2015) Genotype-phenotype characteristics and baseline natural history of heritable neuropathies caused by mutations in the MPZ gene. Brain 138:3180\u20133192. https:\/\/doi.org\/10.1093\/brain\/awv241","journal-title":"Brain"},{"key":"5463_CR29","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1097\/NEN.0b013e318217eba0","volume":"70","author":"C Verhamme","year":"2011","unstructured":"Verhamme C, King RHM, ten Asbroek ALMA et al (2011) Myelin and axon pathology in a long-term study of PMP22-overexpressing mice. J Neuropathol Exp Neurol 70:386\u2013398. https:\/\/doi.org\/10.1097\/NEN.0b013e318217eba0","journal-title":"J Neuropathol Exp Neurol"},{"key":"5463_CR30","doi-asserted-by":"publisher","unstructured":"Moore SM, Jeong E, Zahid M et al (2024) Loss of YAP in Schwann cells improves HNPP pathophysiology. https:\/\/doi.org\/10.1002\/glia.24592. Glia","DOI":"10.1002\/glia.24592"},{"key":"5463_CR31","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.nbd.2005.10.010","volume":"22","author":"J Fortun","year":"2006","unstructured":"Fortun J, Go JC, Li J et al (2006) Alterations in degradative pathways and protein aggregation in a neuropathy model based on PMP22 overexpression. Neurobiol Dis 22:153\u2013164. https:\/\/doi.org\/10.1016\/j.nbd.2005.10.010","journal-title":"Neurobiol Dis"},{"key":"5463_CR32","doi-asserted-by":"publisher","first-page":"10372","DOI":"10.1016\/S0021-9258(18)82211-6","volume":"268","author":"S Pareek","year":"1993","unstructured":"Pareek S, Suter U, Snipes GJ et al (1993) Detection and processing of peripheral myelin protein PMP22 in cultured Schwann cells. J Biol Chem 268:10372\u201310379","journal-title":"J Biol Chem"},{"key":"5463_CR33","doi-asserted-by":"publisher","first-page":"7754","DOI":"10.1523\/JNEUROSCI.17-20-07754.1997","volume":"17","author":"S Pareek","year":"1997","unstructured":"Pareek S, Notterpek L, Snipes GJ et al (1997) Neurons promote the translocation of peripheral myelin protein 22 into myelin. J Neurosci off J Soc Neurosci 17:7754\u20137762. https:\/\/doi.org\/10.1523\/JNEUROSCI.17-20-07754.1997","journal-title":"J Neurosci off J Soc Neurosci"},{"key":"5463_CR34","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.niox.2018.05.009","volume":"78","author":"ES Buys","year":"2018","unstructured":"Buys ES, Zimmer DP, Chickering J et al (2018) Discovery and development of next generation sGC stimulators with diverse multidimensional pharmacology and broad therapeutic potential. Nitric Oxide Biol Chem 78:72\u201380. https:\/\/doi.org\/10.1016\/j.niox.2018.05.009","journal-title":"Nitric Oxide Biol Chem"},{"key":"5463_CR35","doi-asserted-by":"publisher","first-page":"5237","DOI":"10.1038\/s41467-020-18980-x","volume":"11","author":"MJ Ranek","year":"2020","unstructured":"Ranek MJ, Oeing C, Sanchez-Hodge R et al (2020) CHIP phosphorylation by protein kinase G enhances protein quality control and attenuates cardiac ischemic injury. Nat Commun 11:5237. https:\/\/doi.org\/10.1038\/s41467-020-18980-x","journal-title":"Nat Commun"},{"key":"5463_CR36","doi-asserted-by":"publisher","first-page":"e2122482119","DOI":"10.1073\/pnas.2122482119","volume":"119","author":"D Lee","year":"2022","unstructured":"Lee D, Goldberg AL (2022) 26S proteasomes become stably activated upon heat shock when ubiquitination and protein degradation increase. Proc Natl Acad Sci U S A 119:e2122482119. https:\/\/doi.org\/10.1073\/pnas.2122482119","journal-title":"Proc Natl Acad Sci U S A"},{"key":"5463_CR37","doi-asserted-by":"publisher","unstructured":"Costa-Mattioli M, Walter P (2020) The integrated stress response: from mechanism to disease. Science 368. https:\/\/doi.org\/10.1126\/science.aat5314","DOI":"10.1126\/science.aat5314"},{"key":"5463_CR38","doi-asserted-by":"publisher","first-page":"e1008069","DOI":"10.1371\/journal.pgen.1008069","volume":"15","author":"VG Volpi","year":"2019","unstructured":"Volpi VG, Ferri C, Fregno I et al (2019) Schwann cells ER-associated degradation contributes to myelin maintenance in adult nerves and limits demyelination in CMT1B mice. PLoS Genet 15:e1008069. https:\/\/doi.org\/10.1371\/journal.pgen.1008069","journal-title":"PLoS Genet"},{"key":"5463_CR39","doi-asserted-by":"publisher","first-page":"8174","DOI":"10.1523\/JNEUROSCI.0957-20.2020","volume":"40","author":"C Scapin","year":"2020","unstructured":"Scapin C, Ferri C, Pettinato E et al (2020) Phosphorylation of eIF2\u03b1 promotes Schwann Cell differentiation and myelination in CMT1B mice with activated UPR. J Neurosci off J Soc Neurosci 40:8174\u20138187. https:\/\/doi.org\/10.1523\/JNEUROSCI.0957-20.2020","journal-title":"J Neurosci off J Soc Neurosci"},{"key":"5463_CR40","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1126\/science.aaa4484","volume":"348","author":"I Das","year":"2015","unstructured":"Das I, Krzyzosiak A, Schneider K et al (2015) Preventing proteostasis diseases by selective inhibition of a phosphatase regulatory subunit. Science 348:239\u2013242. https:\/\/doi.org\/10.1126\/science.aaa4484","journal-title":"Science"},{"key":"5463_CR41","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1084\/jem.20122005","volume":"210","author":"M D\u2019Antonio","year":"2013","unstructured":"D\u2019Antonio M, Musner N, Scapin C et al (2013) Resetting translational homeostasis restores myelination in Charcot-Marie-tooth disease type 1B mice. J Exp Med 210:821\u2013838. https:\/\/doi.org\/10.1084\/jem.20122005","journal-title":"J Exp Med"},{"key":"5463_CR42","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1038\/s41467-018-03509-0","volume":"9","author":"TA Thibaudeau","year":"2018","unstructured":"Thibaudeau TA, Anderson RT, Smith DM (2018) A common mechanism of proteasome impairment by neurodegenerative disease-associated oligomers. Nat Commun 9:1097. https:\/\/doi.org\/10.1038\/s41467-018-03509-0","journal-title":"Nat Commun"},{"key":"5463_CR43","doi-asserted-by":"publisher","first-page":"4159","DOI":"10.1007\/s12035-022-02838-y","volume":"59","author":"Y Bai","year":"2022","unstructured":"Bai Y, Treins C, Volpi VG et al (2022) Treatment with IFB-088 improves Neuropathy in CMT1A and CMT1B mice. Mol Neurobiol 59:4159\u20134178. https:\/\/doi.org\/10.1007\/s12035-022-02838-y","journal-title":"Mol Neurobiol"},{"key":"5463_CR44","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1002\/embj.201386906","volume":"33","author":"HC Besche","year":"2014","unstructured":"Besche HC, Sha Z, Kukushkin NV et al (2014) Autoubiquitination of the 26S proteasome on Rpn13 regulates breakdown of ubiquitin conjugates. EMBO J 33:1159\u20131176. https:\/\/doi.org\/10.1002\/embj.201386906","journal-title":"EMBO J"},{"key":"5463_CR45","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1093\/cvr\/cvab240","volume":"118","author":"A Petraina","year":"2022","unstructured":"Petraina A, Nogales C, Krahn T et al (2022) Cyclic GMP modulating drugs in cardiovascular diseases: mechanism-based network pharmacology. Cardiovasc Res 118:2085\u20132102. https:\/\/doi.org\/10.1093\/cvr\/cvab240","journal-title":"Cardiovasc Res"}],"container-title":["Cellular and Molecular Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00018-024-05463-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00018-024-05463-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00018-024-05463-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T05:02:59Z","timestamp":1728882179000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00018-024-05463-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,14]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["5463"],"URL":"https:\/\/doi.org\/10.1007\/s00018-024-05463-1","relation":{},"ISSN":["1420-682X","1420-9071"],"issn-type":[{"value":"1420-682X","type":"print"},{"value":"1420-9071","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,14]]},"assertion":[{"value":"29 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Management of the mouse colony and all experiments involving mice were conducted in strict adherence to the protocols approved by the Institutional Animal Care and Use Committees (IACUC) of the Roswell Park Cancer Institute and the State University of New York at Buffalo.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The opinions and assertions expressed herein are those of the authors and do not reflect the official policy or position of the Uniformed Services University of the Health Sciences or the Department of Defense.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclaimers"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate and publish"}},{"value":"GTM and ESB were employees of Cyclerion Therapeutics and may own stock. All other authors report no conflicts of interest.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"434"}}